LordsMed, the global healthcare division of Lord’s Mark Industries, has entered into a distribution partnership with Hindustan Antibiotics Limited (HAL), a leading public-sector drug manufacturer. The healthcare company will manufacture high-quality rapid antigen test kits at its ICMR-approved GMP and ISO-certified facility at Vasai, near Mumbai, Maharashtra, and distribute those kits in government healthcare centers across India at an affordable rate—10 percent less than the average market rates. The broadening of the distribution network is part of LordsMed’s goal of facilitating early-stage healthcare intervention and generating Rs 75 crore in revenue in six months.
LordsMed has recently received ICMR approval to manufacture rapid antigen test kits at its Vasai facility. The company boasts of advanced manufacturing capabilities to produce quick test kits with 98 percent accuracy. LordsMed has deployed German technologies to manufacture rapid test kits for detecting malaria, cardiovascular disease, hepatitis C virus (HCV), HIV, syphilis, hepatitis B surface antigen (HBsAg), dengue, chikungunya, typhoid, COVID, ovulation, and pregnancy.
LordsMed has developed a robust R&D team comprised of experienced microbiologists and doctors and has emerged as the only IVD kit manufacturing company in India, working to roll out saliva-based diagnostic solutions for various diseases. The company has successfully carried out trials of its saliva-based diagnostics kits for diabetes and liver diseases.
Commenting on the partnership with HAL, Sachidanand Upadhyay, MD, and CEO of Lord’s Mark Industries, said, “The distribution partnership with HAL will help us reach out to all parts of the country, including metros, Tier-1, Tier-2, and Tier-3 cities, and rural areas with our affordable and advanced rapid antigen test kits.” The collaboration is a part of our mission to build a robust early-stage healthcare intervention framework and boost the responsiveness of the healthcare ecosystem.
As countries worldwide strengthen their preparedness to prevent another pandemic wave, the Covid rapid antigen test kit will emerge as a critical tool to curb the pandemic impact in India. We are working hard to capture the global and domestic demand spectrums while maintaining strict quality standards and regulatory compliance.
In addition, we also foresee the emergence of saliva as a non-invasive diagnostic method. Our R&D team has been developing saliva-based diagnostic solutions for various diseases. We aim to gain a first-mover advantage by launching advanced saliva-based diagnostic solutions. The larger goal is to play our role in making India atmanirbhar (self-reliant) in diagnostic kit manufacturing.
LordsMed has plans to set up a manufacturing unit in Gujarat by 2023 and another facility in Lucknow, Uttar Pradesh, by 2024 to further boost its manufacturing capabilities and serve the growing market demand. The company also has plans to expand its exports to all countries in Africa and Europe.
